Drug Type Gene therapy |
Synonyms |
Target |
Mechanism Flt3L modulators(Fms-related tyrosine kinase 3 ligand modulators), OX40L modulators(Tumor necrosis factor ligand superfamily member 4 modulators), Gene transference |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Imvaq Therapeutics Corp.Startup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 1 | US | 04 May 2023 | |
Basal Cell Carcinoma | Phase 1 | US | 04 May 2023 | |
Cutaneous Squamous Cell Carcinoma | Phase 1 | US | 04 May 2023 | |
Extramammary Paget Disease | Phase 1 | US | 04 May 2023 | |
Kaposi Sarcoma | Phase 1 | US | 04 May 2023 | |
Melanoma | Phase 1 | US | 04 May 2023 | |
Merkel Cell Carcinoma | Phase 1 | US | 04 May 2023 | |
Refractory Cancer | Phase 1 | US | 04 May 2023 | |
Skin Appendage Carcinoma | Phase 1 | US | 04 May 2023 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | US | 04 May 2023 |